Radiopharm Theranostics Announces Completion Of EOP2 Meeting With FDA Regarding RAD101, Investigational Radiopharmaceutical Imaging Agent For Detection Of Brain Metastases
Constructive FDA interaction provides clear framework for RAD101 pivotal clinical development plan in brain metastases imagingCurrently executing Phase 3 readiness activities in anticipation of FDA meeting minutes in
Radiopharm Theranostics met with the FDA about RAD101, a new brain imaging medicine. The FDA gave them a clear plan for testing it, which is a positive step forward.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.